KR102417487B1 - 지방산 치환기를 가진 egf(a) 유사체 - Google Patents

지방산 치환기를 가진 egf(a) 유사체 Download PDF

Info

Publication number
KR102417487B1
KR102417487B1 KR1020187022105A KR20187022105A KR102417487B1 KR 102417487 B1 KR102417487 B1 KR 102417487B1 KR 1020187022105 A KR1020187022105 A KR 1020187022105A KR 20187022105 A KR20187022105 A KR 20187022105A KR 102417487 B1 KR102417487 B1 KR 102417487B1
Authority
KR
South Korea
Prior art keywords
ethoxy
peptide
egf
amino
measured
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020187022105A
Other languages
English (en)
Korean (ko)
Other versions
KR20180100177A (ko
Inventor
지안이 첸
제스퍼 에프. 라우
야노스 티보 코드라
버지트 비에크조렉
라스 린데로쓰
헨니그 쏘게르센
살카 엘볼 라스무쎈
패트릭 윌리암 게리베이
Original Assignee
노보 노르디스크 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노보 노르디스크 에이/에스 filed Critical 노보 노르디스크 에이/에스
Publication of KR20180100177A publication Critical patent/KR20180100177A/ko
Application granted granted Critical
Publication of KR102417487B1 publication Critical patent/KR102417487B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020187022105A 2016-01-13 2017-01-13 지방산 치환기를 가진 egf(a) 유사체 Expired - Fee Related KR102417487B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/070791 2016-01-13
CN2016070791 2016-01-13
CN2016076580 2016-03-17
CNPCT/CN2016/076580 2016-03-17
EP16195965 2016-10-27
EP16195965.5 2016-10-27
PCT/EP2017/050668 WO2017121850A1 (en) 2016-01-13 2017-01-13 Egf(a) analogues with fatty acid substituents

Publications (2)

Publication Number Publication Date
KR20180100177A KR20180100177A (ko) 2018-09-07
KR102417487B1 true KR102417487B1 (ko) 2022-07-06

Family

ID=57868232

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187022105A Expired - Fee Related KR102417487B1 (ko) 2016-01-13 2017-01-13 지방산 치환기를 가진 egf(a) 유사체

Country Status (26)

Country Link
US (2) US10822385B2 (https=)
EP (1) EP3402811B1 (https=)
JP (2) JP6797926B2 (https=)
KR (1) KR102417487B1 (https=)
CN (1) CN108473550B (https=)
AU (1) AU2017207862B2 (https=)
BR (1) BR112018013820A2 (https=)
CA (1) CA3010756A1 (https=)
CL (1) CL2018001868A1 (https=)
CO (1) CO2018007440A2 (https=)
DK (1) DK3402811T3 (https=)
ES (1) ES2916998T3 (https=)
HR (1) HRP20220720T1 (https=)
HU (1) HUE058647T2 (https=)
IL (1) IL260043A (https=)
LT (1) LT3402811T (https=)
MX (1) MX2018008681A (https=)
MY (1) MY195199A (https=)
PE (1) PE20181376A1 (https=)
PH (1) PH12018501502A1 (https=)
PL (1) PL3402811T3 (https=)
RS (1) RS63298B1 (https=)
RU (1) RU2747877C2 (https=)
SA (1) SA518391996B1 (https=)
SI (1) SI3402811T1 (https=)
WO (1) WO2017121850A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3402811T1 (sl) 2016-01-13 2022-06-30 Novo Nordisk A/S Analogi EGF(A) z maščobnokislinskimi substituenti
SI3402782T1 (sl) 2016-01-13 2020-11-30 Grunenthal Gmbh 8-amino-2-okso-1,3-diaza-spiro-(4,5)-dekanski derivati
CA3011176C (en) 2016-01-13 2023-09-19 Grunenthal Gmbh 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
CA3011180A1 (en) 2016-01-13 2017-07-20 Grunenthal Gmbh 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
SI3402784T1 (sl) 2016-01-13 2020-07-31 Gruenenthal Gmbh Derivati 3-((hetero)aril)-alkil-8-amino-2-okso-1,3-diaza-spiro-(4.5)-dekana
MA49617A (fr) * 2017-07-19 2020-05-27 Novo Nordisk As Analogues d'egf(a), préparation, formulations et utilisations associées
CA3068956A1 (en) 2017-07-19 2019-01-24 Novo Nordisk A/S Bifunctional compounds
US11358994B2 (en) * 2017-07-27 2022-06-14 Saint Louis University Fatty acid modified human epidermal growth factor
IL279363B2 (en) 2018-06-21 2025-12-01 Merck Sharp & Dohme Pcsk9 antagonist compounds
WO2020070276A1 (en) 2018-10-05 2020-04-09 Novo Nordisk A/S Bifunctional compounds comprising insulin peptides and egf(a) peptides
CA3131997A1 (en) 2019-03-22 2020-10-01 3M Innovative Properties Company Fall-protection system with monitoring system
CN110357969B (zh) * 2019-05-27 2022-03-08 北京志道生物科技有限公司 一种GLP1-EGFa异源二聚体蛋白、功能及方法
AU2020326265A1 (en) 2019-08-07 2022-02-03 Novo Nordisk A/S Solid compositions comprising an EGF(A) derivative and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN114641275A (zh) 2019-11-07 2022-06-17 诺和诺德股份有限公司 包含pcsk9抑制剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物
EP4076492A4 (en) 2019-12-20 2024-01-17 Merck Sharp & Dohme LLC PCSK9 ANTAGONIST COMPOUNDS
JP2024527488A (ja) 2021-07-02 2024-07-25 スリーエム イノベイティブ プロパティズ カンパニー 落下防止安全装置と連動される空中リフト
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012017774A1 (ja) 2010-08-02 2012-02-09 日本電気株式会社 偏光子及び発光装置

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
JP2009510999A (ja) 2005-07-29 2009-03-19 エーエムプロテイン コーポレイション キメラ治療剤
JP5721432B2 (ja) 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
MX2010011499A (es) * 2008-04-23 2010-11-12 Amgen Inc Variantes de proproteina neutralizante de convertasa subtilisina kexina de tipo 9 (pcsk9) y sus usos.
WO2009143633A1 (en) 2008-05-30 2009-12-03 Institut De Recherches Cliniques De Montreal Pcsk9 inhibitors and methods of use thereof
TWI516501B (zh) * 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
CN102153652A (zh) 2010-12-10 2011-08-17 浙江大学 一种融合蛋白的表达方法及用途
JP2014510516A (ja) 2011-02-15 2014-05-01 ノヴォ ノルディスク アー／エス 長時間作用性ｉｌ−１受容体アンタゴニスト
WO2012177741A1 (en) * 2011-06-20 2012-12-27 Genentech, Inc. Pcsk9-binding polypeptides and methods of use
AU2012311484B2 (en) * 2011-09-23 2017-04-13 Novo Nordisk A/S Novel glucagon analogues
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
US20140357838A1 (en) * 2011-12-21 2014-12-04 Novo Nordisk A/S N-Terminally Modified Insulin Derivatives
EP2851429B1 (en) 2012-05-18 2019-07-24 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
TW201420606A (zh) 2012-08-22 2014-06-01 Lilly Co Eli 同源二聚體蛋白
JP2015533483A (ja) 2012-09-07 2015-11-26 サノフイ メタボリックシンドロームを治療するための融合タンパク質
EP2986313B1 (en) * 2013-04-18 2019-06-12 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CA2935285A1 (en) 2014-02-21 2015-08-27 Medimmune, Llc Anti-pcsk9-glp-1 fusions and methods for use
US10570184B2 (en) * 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
CN104558198A (zh) 2014-07-25 2015-04-29 成都贝爱特生物科技有限公司 GLP-1类似物和amylin类似物的融合蛋白制备及其用途
US20180207223A1 (en) * 2015-03-19 2018-07-26 Institut De Cardiologie De Montreal Pcsk9 inhibitory polypolypeptides and methods of use
CN105367884A (zh) 2015-11-02 2016-03-02 陈薇 一种绝缘耐火抗辐射的屏蔽电缆材料及其制备方法
SI3402811T1 (sl) 2016-01-13 2022-06-30 Novo Nordisk A/S Analogi EGF(A) z maščobnokislinskimi substituenti
CA3068956A1 (en) 2017-07-19 2019-01-24 Novo Nordisk A/S Bifunctional compounds
MA49617A (fr) 2017-07-19 2020-05-27 Novo Nordisk As Analogues d'egf(a), préparation, formulations et utilisations associées

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012017774A1 (ja) 2010-08-02 2012-02-09 日本電気株式会社 偏光子及び発光装置

Also Published As

Publication number Publication date
CN108473550A (zh) 2018-08-31
AU2017207862A1 (en) 2018-07-05
DK3402811T3 (da) 2022-06-13
US20200407409A1 (en) 2020-12-31
JP6797926B2 (ja) 2020-12-09
PE20181376A1 (es) 2018-09-05
WO2017121850A1 (en) 2017-07-20
PL3402811T3 (pl) 2022-07-11
EP3402811A1 (en) 2018-11-21
JP2019505521A (ja) 2019-02-28
EP3402811B1 (en) 2022-03-30
KR20180100177A (ko) 2018-09-07
RS63298B1 (sr) 2022-07-29
CN108473550B (zh) 2022-11-22
PH12018501502A1 (en) 2019-03-25
US10822385B2 (en) 2020-11-03
US20190016768A1 (en) 2019-01-17
MY195199A (en) 2023-01-11
CO2018007440A2 (es) 2018-09-28
RU2018127882A3 (https=) 2020-06-19
IL260043A (en) 2018-07-31
RU2018127882A (ru) 2020-02-13
MX2018008681A (es) 2018-09-17
SI3402811T1 (sl) 2022-06-30
SA518391996B1 (ar) 2021-07-14
HRP20220720T1 (hr) 2022-09-30
LT3402811T (lt) 2022-06-10
ES2916998T3 (es) 2022-07-06
HUE058647T2 (hu) 2022-09-28
CA3010756A1 (en) 2017-07-20
BR112018013820A2 (pt) 2018-12-11
RU2747877C2 (ru) 2021-05-17
CL2018001868A1 (es) 2018-08-31
AU2017207862B2 (en) 2020-12-17
JP2021035989A (ja) 2021-03-04

Similar Documents

Publication Publication Date Title
KR102417487B1 (ko) 지방산 치환기를 가진 egf(a) 유사체
US11649269B2 (en) Bifunctional compounds comprising insulin peptides and EGF(A) peptides
ES2946247T3 (es) Agonistas parciales del receptor de insulina
JP6006118B2 (ja) Ｇｌｐ−１アナログ及び誘導体
EP2389190B1 (en) Fgf21 derivatives with albumin binder a-b-c-d-e- and their use
CN101005857A (zh) 多肽延长标记
EA020326B1 (ru) Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
CN104185639B (zh) Glp-1前体药物
JP2018505146A (ja) Ｆｇｆ２１誘導体及びその使用
US20200165313A1 (en) Egf(a) analogues, preparation, formulations and uses thereof
KR20230104118A (ko) Glp-1 전구약물 및 이의 용도
AU2018303625A1 (en) Bifunctional compounds
KR20210126088A (ko) 지속성 glp-2 유사체
HK1262866B (en) Egf(a) analogues with fatty acid substituents
EP4204441A1 (en) Insulin receptor partial agonists
EA041034B1 (ru) Частичные агонисты инсулинового рецептора

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250702

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250702

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250702